Combined treatment with glucagon-like peptide-1 (GLP-1) and nicotine has been shown to improve obesity by acting on the hypothalamic and mesocorticolimbic pathways. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.